In DLBCL, TP53 mutations are found in ∼20% of cases and are significantly and independently associated with poor overall survival of both activated B‐cell like (ABC) and germinal centre B‐cell like (GCB) DLBCL treated with R‐CHOP 22, 23. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.